Physician profile
Thomas Hadley Ledyard
NPI 1083621304
$140.05
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $39.48.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Clovis Oncology, INC. | $25.83 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.60 | 2019 | |
| Genzyme Corporation | $16.49 | 2019 | |
| Amgen INC. | $14.79 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $14.16 | 2019 | |
| Rigel Pharmaceuticals, INC. | $13.67 | 2020 | |
| Eisai INC. | $13.34 | 2020 | |
| Aurobindo Pharma USA, INC. | $12.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $12.47 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ledyard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.